Detalhe da pesquisa
1.
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
N Engl J Med
; 387(5): 397-407, 2022 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921449
2.
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Lancet
; 401(10373): 294-302, 2023 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709074
3.
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.
NPJ Vaccines
; 9(1): 67, 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38553525
4.
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
Lancet Infect Dis
; 23(5): 578-588, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708738
5.
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Lancet Infect Dis
; 23(12): 1408-1417, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37544326
6.
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
Curr Opin HIV AIDS
; 17(4): 247-257, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35762380
7.
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Lancet Infect Dis
; 22(8): 1210-1220, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35568049
8.
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.
EClinicalMedicine
; 48: 101477, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35783486